Company intelligence / Profile preview
ISISPHARMA
- Ownership
- Private
- Employees
- ~159
- Development stage
- Other
Overview
Isispharma is a French pharmaceutical laboratory specializing in dermatology and skincare solutions. Founded in 1987 by pharmacist Christian Diehl, the company focuses on the concept of skin homeostasis to restore the skin's natural balance. Their product portfolio addresses a wide range of dermatological conditions, including hyperpigmentation, rosacea, acne, and vitiligo. Isispharma operates as part of the Dewavrin Group and distributes its products in over 80 countries. The company emphasizes clinical research and collaborates closely with healthcare professionals to develop effective dermo-cosmetic treatments. Their core brands, such as Neotone and Ruboril, are widely recognized for their targeted efficacy and safety profiles.
- Therapeutic areas
- Dermatology
- Modalities
- CosmeticEmollientPlant extractTopical
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on ISISPHARMA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISISPHARMA.